Ceribell vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ceribell (Nasdaq: CBLL) makes the only FDA-cleared AI point-of-care EEG for seizure detection in all patient ages; reported $89.1M revenue in 2025 (+36% YoY) with 2026 guidance of $111–$115M.
About
Ceribell is a commercial-stage medical technology company that has reimagined the electroencephalogram (EEG) for the acute care setting. Its flagship product is a rapid-application, disposable EEG system with an AI algorithm called Clarity that detects electrographic seizures in real time. The platform is FDA-cleared for use across all patient ages — from pre-term neonates through adults — making it the only point-of-care EEG with that breadth of clearance. In December 2025, Ceribell received additional FDA 510(k) clearance for its AI-powered delirium monitoring solution, the first and only FDA-cleared delirium screening and monitoring device.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.